TITLE

Roflumilast Tablets (Daliresp®)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
April 2011
SOURCE
Internal Medicine Alert;4/29/2011, Vol. 33 Issue 8, p62
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on the drug Roflumilast, an oral phosphodiesterase 4 (PDE4) inhibitor used to treat chronic osbtructive pulmonary disease (COPD), with its brand name Daliresp from Forest Pharmaceuticals Inc.
ACCESSION #
60823550

 

Related Articles

  • Roflumilast (Daliresp) for Chronic Obstructive Pulmonary Disease. BAZALDUA, ORALIA V.; DAVIDSON, DEWAYNE A.; BABB, FRANKLYN C. // American Family Physician;2/15/2014, Vol. 89 Issue 4, p300 

    This article evaluates the oral selective phosphodiesterase-4 inhibitor Roflumilast (Daliresp) for chronic obstructive pulmonary disease (COPD).

  • NEW PHARMACOLOGICAL TREATMENTS FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PUMONARY DISEASE (COPD). Larocca, Nancy Elizabeth; Moreno, Dolores; Garmendia, Jenny Valentina; De Sanctis, Juan Bautista // Biomedical Papers of the Medical Faculty of Palacky University i;Mar2011, Vol. 155 Issue 1, p43 

    Background. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized mainly by pulmonary airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with abnormal inflammatory response of the lung to...

  • Pharmacovigilance Analysis of Adverse Psychiatric Events and Suicidality Reported for Roflumilast, an Add-On COPD Therapy. Ali, Ayad K. // British Journal of Pharmaceutical Research;Oct-Dec2013, Vol. 3 Issue 4, p972 

    Aims: Roflumilast is a phosphodiesterase-4-inhibitor used as add-on therapy to long- acting bronchodilators in chronic obstructive pulmonary disease. Although roflumilast is well tolerated, there have been concerns regarding psychiatric problems, including suicide tendencies. This study aims to...

  • Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Samyshkin, Yevgeniy; Kotchie, Robert; Mörk, Ann-Christin; Briggs, Andrew; Bateman, Eric // European Journal of Health Economics;Jan2014, Vol. 15 Issue 1, p69 

    Objective: To estimate the cost-effectiveness of adding a selective phosphodiesterase-4 inhibitor, roflumilast, to a long-acting bronchodilator therapy (LABA) for the treatment of patients with severe-to-very severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis...

  • Oral Option Shows Promise for COPD.  // Journal of Gerontological Nursing;Dec2009, Vol. 35 Issue 12, p52 

    The author reports that a monthly oral treatment for chronic obstructive pulmonary disease (COPD) has been found to improve lung function in patients with moderate to severe COPD. Daxas (roflumilast), a phosphodiesterase 4 inhibitor, is in Phase III trials and would be the first drug of its...

  • Drugs in Clinical Development for Chronic Obstructive Pulmonary Disease.  // Pharmaceutical Medicine - New Zealand;2011, Vol. 25 Issue 4, p251 

    The article discusses advances in the pharmacotherapy of chronic obstructive pulmonary disease (COPD). It cites bronchitis, emphysema and mucus hypersecretion as conditions underlying COPD. Treatment options for suppressing pulmonary inflammation in COPD are roflumilast and protease inhibition....

  • Roflumilast.  // AHFS Consumer Medication Information;Feb2018, p1 

    Roflumilast is used in people with severe chronic obstructive pulmonary disease (COPD; a group of diseases that affect the lungs and airways) to reduce the number of episodes or worsening of COPD symptoms. Roflumilast is in a class of medications called phosphodiesterase inhibitors. It works by...

  • E merging Therapeutic Options for the Management of COPD. Reid, Debra J.; Pham, Nga T. // Clinical Medicine Insights: Circulatory, Respiratory & Pulmonary;2013, Issue 7, p7 

    Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators...

  • Roflumilast: A new phosphodiesterase 4 inhibitor for chronic obstructive pulmonary disease. Baker, Erica L.; Baker, William L. // Formulary;Jan2010, Vol. 45 Issue 1, p6 

    The article discusses the use of roflumilast for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD). Roflumilast is a phosphodiesterase 4 inhibitor under review by the U.S. Food and Drug Administration (FDA). Studies demonstrate that roflumilast improves lung...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics